#United States #Clinical Trials #Biopharma #Pleasanton #Veeva CTMS

Enhanced Efficiency in Clinical Trials with Veeva CTMS

In a significant development for the biopharma industry, Veeva Systems (NYSE: VEEV) has reported that over 200 companies have integrated Veeva Clinical Trial Management System (CTMS) into their operations. This includes 17 of the top 20 biopharmaceutical firms, highlighting the platform's pivotal role in executing faster and more efficient clinical trials.

As clinical studies become increasingly intricate and data volumes surge, biopharmaceutical companies (biopharmas) and Contract Research Organizations (CROs) have found a solution for their operational challenges in Veeva CTMS. By centralizing datasets and documentation, Veeva CTMS streamlines processes and enhances collaboration among stakeholders. Bonne Adams, vice president of operations at Inhibrx, noted, “Veeva CTMS is the central hub of our trials, allowing study metrics and documents to flow seamlessly across our ecosystem.” This connected platform not only saves time for lean teams but also optimizes interactions with CRO partners.

Regardless of whether biopharmas insource or outsource their clinical studies, Veeva CTMS empowers clinical teams to manage trials proactively. This enables them to swiftly identify potential issues and address them, thereby ensuring a high standard of trial execution. The system's flexible and scalable nature allows companies to accelerate their trial processes while still delivering high-quality data that complies with global regulations, such as ICH E6(R2) and (R3).

Veeva is continually innovating to help biopharmas adapt to changes in trial operating models and evolving regulations. Recent advancements in Veeva CTMS have included automated data transfers from CROs to sponsors, which enhance visibility in trial management, and improved oversight issue tracking that allows for quicker problem resolution. These enhancements enable companies to effectively manage both insourced and outsourced trials, guaranteeing both speed and agility in the process.

Henry Galio, vice president of Veeva CTMS strategy, emphasized the importance of scalability in modern clinical trial management systems: “To provide this flexibility, we're delivering new capabilities for Veeva CTMS through our three product releases per year, continuously advancing to help the industry work better together and accelerate execution.”

The increasing adoption of Veeva CTMS reflects a broader trend of companies simplifying their trial operations while maintaining compliance, no matter the operational framework. This system is part of the Veeva Clinical Platform, recognized as the most comprehensive and high-quality platform for achieving faster and more efficient clinical trials.

For industry stakeholders interested in learning more about Veeva CTMS, the technology will be showcased at the SCOPE 2025 conference in Orlando from February 3 to 6, 2025, at booth 916.

About Veeva Systems

Veeva Systems stands as a global leader in providing cloud software solutions specifically tailored for the life sciences sector. With a commitment to innovation and customer success, Veeva serves an extensive client base of over 1,000 customers, which includes some of the world’s largest biopharmaceutical firms as well as emerging biotech companies. As a Public Benefit Corporation, Veeva prioritizes the interests of all stakeholders, including customers, employees, and shareholders. For further information, visit veeva.com.

In conclusion, Veeva CTMS is setting a new standard in the biopharma industry that not only enhances trial management efficiency but empowers companies to navigate the complexities of modern clinical research successfully.